Trial Profile
A Phase III, Multicentre, Double Blinded Study In Patients With Chronic Hepatitis C Who Are Non-Responders To Prior Peginterferon Alpha + Ribavirin Therapy Comparing Treatment With Thymosin Alpha 1 + Peginterferon Alpha-2a Plus Ribavirin With Peginterferon Alpha-2a + Ribavirin + Placebo.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2012
Price :
$35
*
At a glance
- Drugs Thymalfasin (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors sigma-tau SpA
- 01 Jan 2012 Results published in the Journal of Viral Hepatitis.
- 09 Aug 2010 Official title, actual end date (July 2009) added as reported by ClinicalTrials.gov.
- 09 Aug 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).